文献速递消化道肿瘤放疗放疗物理与技术

剂量递增IMRT治疗不可手术局部晚期食管癌的单中心I期可行性研究

A single-institution phase I feasibility study of dose-escalated IMRT for non-operative locally advanced esophageal carcinoma.
PubMed 文献 · Clin Transl Radiat Oncol · 2021-06-29

主要终点为4-5级毒性率<15%,实际发生1例5级和1例4级心脏事件;3年OS为48.6%,PFS为28.5%,远处失败率达一半,局部区域复发10例(38%)。

要点

  • IMRT剂量递增(60 Gy同步推量)在局部晚期食管癌中可行性达标,但毒性和化疗依从性仍受限。
  • 3年OS 48.6%、PFS 28.5%,远处失败常见,局部区域复发10例(38%)。

核心结论

  • 研究达到可行性主要终点,但毒性和治疗依从性仍是限制因素,疗效与历史对照相似。
  • 剂量递增在局部晚期食管癌根治性治疗中的作用仍不确定。

研究设计与样本

  • 肿瘤区接受60 Gy/30次,高危区接受54 Gy同步整合推量,同步化疗以顺铂/5-FU为主。
  • 主要终点为4-5级毒性率<15%,次要终点包括OS、PFS、局部区域复发和远处复发。

主要发现

  • 中位随访17.6个月(范围0.1至152.0),多数为AJCC第7版III期(54%)、远端食管原发(81%)、腺癌(85%)。
  • 发生1例5级和1例4级心脏事件,均发生在放化疗期间且未满50 Gy。
  • 3年OS为48.6%(95% CI:32.5至72.2%),PFS为28.5%(95% CI:14.6至55.5%)。
  • 一半患者出现远处失败,局部区域复发10例(38%),其中孤立性局部区域复发5例。

关键数值与推荐

  • 可行性主要终点定义为4-5级毒性率<15%。
  • 放疗剂量:肿瘤区60 Gy/30次,高危区54 Gy同步整合推量。

临床怎么用

  • IMRT同步整合推量行剂量递增在局部晚期食管癌中可行,但需关注心脏毒性和化疗依从性。
  • 该方案疗效未超越历史对照,剂量递增的临床价值尚待进一步研究确定。

局限性

  • 仅55%完成2周期同步化疗,治疗依从性可能影响结果解读。
  • 作者指出剂量递增在局部晚期食管癌根治性治疗中的作用仍不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Radiation dose escalation to improve poor outcomes with chemoradiation in locally advanced esophageal carcinoma is limited in part by increased toxicity. This Phase I study investigates the use of IMRT to improve tolerability of dose escalation. MATERIALS AND METHODS: A single-institution, prospective study was conducted between 2007 and 2013 for individuals with inoperable esophageal carcinoma. Gross disease received 60 Gy in 30 fractions and at-risk sites received 54 Gy with simultaneous integrated boost. Concurrent chemotherapy primarily consisted of cisplatin/5-FU. The primary objective was to assess feasibility (<15% rate of grade 4-5 toxicity). Secondary objectives included assessment of overall survival (OS), progression free survival (PFS), and locoregional (LRR) and distant recurrence. RESULTS: Twenty-six patients were enrolled with median follow up of 17.6 months (range 0.1 to 152.0). The majority were AJCC 7th edition Stage III (54%), distal esophagus primary (81%), and adenocarcinoma histology (85%). Twenty-one patients (81%) completed their course of radiation therapy, while only 55% received 2 cycles of concurrent cisplatin/5-FU. One grade 5 and one grade 4 cardiac event occurred, both during chemoradiation and before receiving 50 Gy. The 3-year OS was 48.6% (95% CI: 32.5 to 72.2%) and PFS was 28.5% (95% CI: 14.6 to 55.5%). Half developed distant failure with LRR occurring in 10 patients (38%), isolated in 5 patients. CONCLUSION: While feasibility was demonstrated, toxicity and compliance remained limiting factors with outcomes similar to historical controls. There remains an uncertain role for dose escalation in definitive management of locally advanced esophageal cancer.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Vlacich G, Ballard A, Badiyan SN, et al. A single-institution phase I feasibility study of dose-escalated IMRT for non-operative locally advanced esophageal carcinoma. Clin Transl Radiat Oncol. 2021. PMID: 34278011. doi:10.1016/j.ctro.2021.06.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。